Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

NCT01831505 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them

Sponsor

Presage Biosciences

Collaborators

[object Object]
[object Object]
[object Object]